No Data
Should Weakness in LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.'s (HKG:2291) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
Xintai Medical (02291.HK) announces a profit alert: expected net profit for the year 2024 is between 0.23 billion and 0.26 billion yuan.
On March 21, 2023, Gelonghui reported that Xintai Medical (02291.HK) announced that for the fiscal year ending December 31, 2024 ("reporting period"), the Group expects to record a profit attributable to equity holders of the company between approximately RMB 0.23 billion and approximately RMB 0.26 billion, compared to a profit attributable to equity holders of the company of RMB 0.1515 billion for the fiscal year ending December 31, 2023. The announcement stated that the expected increase in profit attributable to Shareholders is mainly due to the significant increase in sales of the Group's bioabsorbable occluder product line during the reporting period compared to the fiscal year ending December 31, 2023.
Express News | Lepu Scientech Medical Technology Shanghai - Increase in Net Profit Due to Higher Sales of Biodegradable Occluder Products in FY
Express News | Lepu Scientech Medical Technology Shanghai - Expected Net Profit of RMB230 Mln to RMB260 Mln for 2024
SCIENTECH: INSIDE INFORMATIONPOSITIVE PROFIT ALERT
Xintai Medical (02291.HK) will hold a Board of Directors meeting on March 28 to consider and approve the annual performance.
Gelonghui, March 18 - Heart Tech Medical (02291.HK) announced that the Board of Directors will hold a meeting on March 28, 2025 (Friday) to consider and approve the annual performance of the company and its subsidiaries for the year ending December 31, 2024, and its release, as well as to consider the proposal for the final dividend distribution (if any).
